Qiagen (NYSE:QGEN) Releases FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.380-2.380 for the period, compared to the consensus earnings per share estimate of 2.360. The company issued revenue guidance of -, compared to the consensus revenue estimate of $2.1 billion.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on QGEN. UBS Group lifted their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Cowen reiterated a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. Barclays set a $53.00 target price on shares of Qiagen and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Qiagen in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average target price of $49.69.

Qiagen Stock Down 3.4%

Shares of Qiagen stock traded down $1.55 during trading on Tuesday, reaching $44.13. The stock had a trading volume of 3,157,675 shares, compared to its average volume of 1,335,998. The company has a market capitalization of $9.81 billion, a price-to-earnings ratio of 26.07, a P/E/G ratio of 2.48 and a beta of 0.66. The stock has a fifty day moving average price of $46.75 and a two-hundred day moving average price of $46.46. Qiagen has a 52 week low of $37.63 and a 52 week high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last released its earnings results on Tuesday, November 4th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.02. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Sell-side analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.

Institutional Trading of Qiagen

Several hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC raised its stake in shares of Qiagen by 226.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after acquiring an additional 1,802 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Qiagen by 101.4% during the second quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock valued at $185,000 after acquiring an additional 1,951 shares during the last quarter. Pitcairn Co. bought a new position in shares of Qiagen during the second quarter valued at $208,000. Captrust Financial Advisors bought a new position in shares of Qiagen during the second quarter valued at $221,000. Finally, United Services Automobile Association acquired a new stake in shares of Qiagen during the first quarter worth $239,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.